Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
BETAPACE vs BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Category C
Category A/B
Beta-Blocker
Beta-Blocker